JP7456643B2 - 核酸分子の製造方法、生体用材料、および生体用材料の製造方法 - Google Patents
核酸分子の製造方法、生体用材料、および生体用材料の製造方法 Download PDFInfo
- Publication number
- JP7456643B2 JP7456643B2 JP2021553692A JP2021553692A JP7456643B2 JP 7456643 B2 JP7456643 B2 JP 7456643B2 JP 2021553692 A JP2021553692 A JP 2021553692A JP 2021553692 A JP2021553692 A JP 2021553692A JP 7456643 B2 JP7456643 B2 JP 7456643B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- vegf
- acid molecule
- binding
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/668,717 | 2019-10-30 | ||
| US16/668,717 US11613748B2 (en) | 2019-10-30 | 2019-10-30 | Method for producing nucleic acid molecule, biomaterial, and method for producing biomaterial |
| JPPCT/JP2020/018142 | 2020-04-28 | ||
| PCT/JP2020/018142 WO2021084782A1 (en) | 2019-10-30 | 2020-04-28 | Method for producing nucleic acid molecule, biomaterial, and method for producing biomaterial |
| PCT/JP2020/040687 WO2021085554A1 (ja) | 2019-10-30 | 2020-10-29 | 核酸分子の製造方法、生体用材料、および生体用材料の製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021085554A1 JPWO2021085554A1 (cg-RX-API-DMAC7.html) | 2021-05-06 |
| JPWO2021085554A5 JPWO2021085554A5 (cg-RX-API-DMAC7.html) | 2022-07-07 |
| JP7456643B2 true JP7456643B2 (ja) | 2024-03-27 |
Family
ID=75688434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553692A Active JP7456643B2 (ja) | 2019-10-30 | 2020-10-29 | 核酸分子の製造方法、生体用材料、および生体用材料の製造方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US11613748B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7456643B2 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2021084782A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026015902A1 (en) * | 2024-07-12 | 2026-01-15 | The Regents Of The University Of California | Synthetic matrix for stem cell encapsulation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014128289A1 (en) | 2013-02-22 | 2014-08-28 | Lumetti, Simone | Biomedical device implantable in bone and/or cartilaginous tissue, and corresponding method to manufacture said biomedical device |
-
2019
- 2019-10-30 US US16/668,717 patent/US11613748B2/en active Active
-
2020
- 2020-04-28 WO PCT/JP2020/018142 patent/WO2021084782A1/en not_active Ceased
- 2020-10-29 US US17/773,461 patent/US12595480B2/en active Active
- 2020-10-29 JP JP2021553692A patent/JP7456643B2/ja active Active
- 2020-10-29 WO PCT/JP2020/040687 patent/WO2021085554A1/ja not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014128289A1 (en) | 2013-02-22 | 2014-08-28 | Lumetti, Simone | Biomedical device implantable in bone and/or cartilaginous tissue, and corresponding method to manufacture said biomedical device |
Non-Patent Citations (3)
| Title |
|---|
| Biomaterials,2017年07月10日,vol. 142,pp. 52-61 |
| 森下裕貴,2016年度実績報告書 機能性材料の開発を加速させる新規RNAアプタマー修飾医用材料の創出(研究課題/領域番号 15J10771),KAKENHI-PROJECT [online],2018年01月16日,retrieved 2020/12/23, KAKEN, which retrieved from the internet,<URL: https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-15J10771/15J107712016jisseki/> |
| 森下裕貴他,血管内皮細胞増殖因子を特異的に補足するRNAアプタマー修飾材料の機能評価,第39回日本バイオマテリアル学会大会予稿集,2017年11月13日,vol. 39,p. 157 (1P-103-I) |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2021085554A1 (cg-RX-API-DMAC7.html) | 2021-05-06 |
| US20220396792A1 (en) | 2022-12-15 |
| WO2021085554A1 (ja) | 2021-05-06 |
| WO2021084782A1 (en) | 2021-05-06 |
| US12595480B2 (en) | 2026-04-07 |
| US11613748B2 (en) | 2023-03-28 |
| US20210130820A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sakiyama-Elbert et al. | Development of growth factor fusion proteins for cell‐triggered drug delivery | |
| US6180348B1 (en) | Method of isolating target specific oligonucleotide ligands | |
| KR101399677B1 (ko) | Pdgf의 제어 방출을 위한 피브린 젤 및 그의 용도 | |
| Zustiak et al. | Influence of cell-adhesive peptide ligands on poly (ethylene glycol) hydrogel physical, mechanical and transport properties | |
| RU2624036C2 (ru) | Структуры слитого белка шелка пауков для связывания с органической мишенью | |
| Robinson et al. | Differential effects of substrate modulus on human vascular endothelial, smooth muscle, and fibroblastic cells | |
| Nakaji-Hirabayashi et al. | Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier | |
| CA2572446A1 (en) | Combinatorial selection of phosphorothioate aptamers for tgf-beta | |
| WO1998043686A1 (en) | Enzyme-mediated modification of fibrin for tissue engineering | |
| JP6412866B2 (ja) | 有機ターゲットに結合するための反復断片を持たないクモ糸融合タンパク質の構造 | |
| TW201706411A (zh) | 結合於血管內皮生長因子受體之核酸適體 | |
| US12595480B2 (en) | Method for producing nucleic acid molecule, biomaterial, and method for producing biomaterial | |
| TW201309720A (zh) | 胜肽庫 | |
| KR101667149B1 (ko) | 표적 단백질 또는 표적 펩타이드 검출용 미세 유동 장치, 이의 제조방법 및 이를 이용한 표적 단백질 또는 표적 펩타이드 검출 방법 | |
| CA3125556A1 (en) | Methods of producing high diversity peptide libraries and promoting protein folding | |
| Abe et al. | Structure and function of engineered stromal cell-derived factor-1α | |
| EP1668133A1 (en) | Coiled-coil fusion proteins comprising cell receptor domains | |
| Parvez | Aptamers for Alginate Hydrogels and Diabetic Wound Healing | |
| JP7405400B2 (ja) | 核酸分子およびその用途 | |
| WO2025058014A1 (ja) | 核酸アプタマー及び当該核酸アプタマーを含む骨再生誘導材 | |
| Bahri et al. | A multifunctional fusion peptide for tethering to hydroxyapatite and selective capture of bone morphogenetic protein from extracellular milieu | |
| KR20210134990A (ko) | 재조합 GpIbα 수용체 단백질을 포함하는 조성물 | |
| JP6963221B2 (ja) | 核酸分子およびその用途 | |
| KR20180089144A (ko) | 피브로넥틴 edb을 골격으로 한 비항체 단백질 스캐폴드 라이브러리 및 그의 용도 | |
| CN120283055A (zh) | 异多聚体蛋白质的制造方法、蛋白质、核酸、表达载体、转化体、以及蛋白质的制造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220421 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220421 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20220630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230314 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231129 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240213 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240307 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7456643 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |